# Flexus Biosciences

**Canonical:** https://apis.io/providers/flexus-biosciences/  
**APIs profiled:** 0

Flexus Biosciences was a South San Francisco / San Carlos, California biotechnology company founded in 2013 to develop small-molecule cancer immunotherapies, most notably inhibitors of the IDO/TDO immunosuppressive pathway (lead IDO1 program F001287). Backed by Kleiner Perkins and The Column Group, it was acquired by Bristol-Myers Squibb in February 2015 for up to roughly $1.25 billion (about $800M upfront) to expand BMS's immuno-oncology pipeline. The company no longer operates independently; its domain redirects to the Bristol-Myers Squibb acquisition announcement. It publishes no public developer portal, documentation, or API, so this profile carries company identity only and no technical API artifacts.

## Kin Score — 2.2 / 100 (minimal)

Scored 2026-08-20 under rubric 0.12.0. Trend: flat (+0.0 from 2.2).

| Facet | Score |
|---|---|
| Discoverability | 50.0 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 0.0 |
| Commercial Clarity | 0.0 |
| Access Clarity | 0.0 |

Regulatory layer — **Health**: 0.0 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## Access

Unknown — onboarding: unknown, pricing: unknown, trial: no (confidence: low).

## Tags

Company, Healthcare, Biotechnology, Pharmaceuticals, Immuno-Oncology, Cancer, Drug Discovery, Acquired

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/flexus-biosciences/). Scores are computed from the provider's own public artifacts under a published rubric.